Which has the lower trailing P/E, BIO or GMED?

GMED has the lower trailing P/E: BIO trades at 47.11 and GMED at 21.22. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BIO or GMED?

Over the past five years, GMED grew revenue faster — BIO at a 0.29% CAGR versus GMED at 27.65%.

Is BIO or GMED more profitable?

GMED runs the higher net margin — BIO at 8.59% versus GMED at 17.03%.

How have BIO and GMED total returns compared?

Over the past 10 years, BIO delivered 9.90% and GMED delivered 13.76% annualized total return. Past performance doesn't predict future results.

Bio-Rad Laboratories, Inc. (BIO) vs Globus Medical, Inc. (GMED)

A side-by-side comparison of Bio-Rad Laboratories, Inc. and Globus Medical, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 27, 2026. Differences are shown without an overall score or investment verdict.

BIO

Bio-Rad Laboratories, Inc.

$10.50B

$389.94HealthcareDelayed quote: Aug 27, 2026, 4:00 PM EDT

GMED

Globus Medical, Inc.

$11.13B

$82.54HealthcareDelayed quote: Aug 27, 2026, 4:00 PM EDT

Total return — BIO vs GMED

growth of $100 · dividends reinvested · last 10y

BIO +158.0% (+9.9%/yr)GMED +264.3% (+13.8%/yr)GMED compounded faster over this window

BIO GMED

BIO vs GMED: by the numbers

•GMED is the larger company ($11.13B vs $10.50B market cap).
•GMED trades at the lower trailing earnings multiple (21.22 vs 47.11 P/E), one valuation lens rather than an overall verdict.
•GMED converts more revenue to profit (17.03% vs 8.59% net margin).
•GMED grew revenue faster over the past five years (27.65% vs 0.29% CAGR).

Metrics side by side

Valuation

Metric	BIO	GMED
P/E ratio	47.11	21.22
Forward P/E	40.31	16.57
P/S ratio	4.02	3.63
P/B ratio	1.45	2.39
EV / EBITDA	29.04	11.79
FCF yield	3.39%	6.58%

Profitability

Metric	BIO	GMED
Gross margin	51.90%	68.55%
Operating margin	9.08%	20.75%
Net margin	8.59%	17.03%
ROE	3.10%	11.23%
ROIC	1.54%	10.49%

Growth (annualized)

Metric	BIO	GMED
Revenue CAGR (5Y)	0.29%	27.65%
EPS CAGR (5Y)	-26.27%	30.79%
FCF CAGR (5Y)	-9.65%	29.93%
Total return CAGR (5Y)	-13.40%	0.22%

Frequently asked

Which has the lower trailing P/E, BIO or GMED?: GMED has the lower trailing P/E: BIO trades at 47.11 and GMED at 21.22. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BIO or GMED?: Over the past five years, GMED grew revenue faster — BIO at a 0.29% CAGR versus GMED at 27.65%.
Is BIO or GMED more profitable?: GMED runs the higher net margin — BIO at 8.59% versus GMED at 17.03%.
How have BIO and GMED total returns compared?: Over the past 10 years, BIO delivered 9.90% and GMED delivered 13.76% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIO analysis Full GMED analysis Interactive comparison tool

Dig into the metrics

Bio-Rad Laboratories P/E ratio Globus Medical P/E ratio Bio-Rad Laboratories ROE Globus Medical ROE Bio-Rad Laboratories operating margin Globus Medical operating margin Bio-Rad Laboratories revenue growth Globus Medical revenue growth Bio-Rad Laboratories free cash flow Globus Medical free cash flow

Bio-Rad Laboratories & Globus Medical appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 27, 2026.